Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.42 |
| ▸ | MVD | P53602 | 3/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45357 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL8851949 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL10834666 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL28494654 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL554667 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL36089 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL28767268 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL140392 | 1.00 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Ammonia Solution, Strong SCHEMBL21679659 | 0.96 | FDPS (0.60) | FDPSBLMTDP1BTN3A1MVD | |
| Ammonia Solution, Strong SCHEMBL21679658 | 0.96 | FDPS (0.60) | FDPSBLMTDP1BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055565-A1 | POLYMERASE COMPOSITIONS & METHODS | Life Technologies Corporation (US) | 2023-02-23 | — | — | US | disclosed |
| US-20160265045-A1 | POLYMERASE COMPOSITIONS AND METHODS | Life Technologies Corporation | 2016-09-15 | — | — | US | disclosed |
| US-20150247136-A1 | POLYMERASE COMPOSITIONS AND METHODS | Life Technologies Corporation | 2015-09-03 | — | — | US | disclosed |
| EP-2621273-A2 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | Normoxys, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120322057-A1 | POLYMERASE COMPOSITIONS AND METHODS | Life Technologies Corporation (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012045009-A2 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | NORMOXYS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20110014612-A1 | POLYMERASE COMPOSITIONS & METHODS | Life Technologies Corporation (US) | 2011-01-20 | — | — | US | disclosed |
| US-20070264667-A1 | Method and system for assaying transferase activity | GELLIBOLIAN ROBERT | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014612-A1 | POLYMERASE COMPOSITIONS & METHODS | POLN, POLI, POLRMT | FDPS 613/4885BLM 207/4885TDP1 110/4885 |
| US-20230055565-A1 | POLYMERASE COMPOSITIONS & METHODS | POLN, POLI, POLRMT | FDPS 613/4885BLM 207/4885TDP1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.